FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Paul Guastalla

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

France

Co-author Network

Publications

TOP 3
F Couder; François Golfier; Jean-Paul Guastalla; Touria Hajri; J Massardier; Fabien Vaudoyer; Daniel Raudrant
[Living birth after partial hysterectomy for chemorefractory gestational choriocarcinoma].
David Pérol; Xavier Pivot; Jocelyne Provençal; Cécile Agostini; Thomas Bachelot; Agathe Bajard; David Coeffic; Jean-Paul Guastalla; Anne-Claire Hardy-Bessard; JP Jacquin; Jean-Pierre Martin; ISABELLE RAY COQUARD
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
Irène Asmane; Agathe Bajard; Jean-Pierre Bergerat; David Coeffic; Armelle Dufresne; Jean-Paul Guastalla; Jean-Emmanuel Kurtz; Intidhar Labidi Galy; Pierre Meeus; Isabelle Moullet; Olivier Tredan; Lionel Vincent; Philippe Ardisson; ISABELLE RAY COQUARD
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Paul Guastalla (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: F Couder; François Golfier; Jean-Paul Guastalla; Touria Hajri; J Massardier; Fabien Vaudoyer; Daniel Raudrant
[Living birth after partial hysterectomy for chemorefractory gestational choriocarcinoma].
Gynécologie, obstétrique & fertilité 2012;40(6):376-8.
2012: David Pérol; Xavier Pivot; Jocelyne Provençal; Cécile Agostini; Thomas Bachelot; Agathe Bajard; David Coeffic; Jean-Paul Guastalla; Anne-Claire Hardy-Bessard; JP Jacquin; Jean-Pierre Martin; ISABELLE RAY COQUARD
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
BMC cancer 2012;12():603.
2011: Irène Asmane; Agathe Bajard; Jean-Pierre Bergerat; David Coeffic; Armelle Dufresne; Jean-Paul Guastalla; Jean-Emmanuel Kurtz; Intidhar Labidi Galy; Pierre Meeus; Isabelle Moullet; Olivier Tredan; Lionel Vincent; Philippe Ardisson; ISABELLE RAY COQUARD
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Bulletin du cancer 2011;98(9):80-9.
2011: Thomas Bachelot; Agathe Bajard; Martial Boisseau; David Coeffic; Dominique Dramais; Rose-Marie Ferri-Dessens; Jean-Paul Guastalla; Régis Kaphan; Corina Oprea; Jocelyne Provencal; ISABELLE RAY COQUARD; Cécile Agostini; David Perol
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Oncology 2011;80(3-4):262-8.
2010: Olivier Trédan; Agathe Bajard; Anne Meunier; Pascale Roux; Ingrid Fiorletta; Thérèse Gargi; Thomas Bachelot; Jean-Paul Guastalla; Yolande Lallemand; Christelle Faure; David Pérol; Patrick Bachmann
Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study.
Clinical nutrition (Edinburgh, Scotland) 2010;29(2):187-91.
2010: Philippe A Cassier; Aude Duret; Olivier Trédan; Nicolas Carrabin; Pierre Méeus; Isabelle Treilleux; Jean-Paul Guastalla; ISABELLE RAY COQUARD
New developments in treatment of ovarian carcinoma: focus on trabectedin.
Cancer management and research 2010;2():233-42.
2010: Jean-Marc Extra; Eric C Antoine; Anne Vincent-Salomon; Thierry Delozier; Pierre Kerbrat; Anne Bethune-Volters; Jean-Paul Guastalla; Marc Spielmann; Louis Mauriac; Jean-Louis Misset; Daniel Serin; Mario Campone; Christophe Hebert; Céline Remblier; Loïc Bergougnoux; Frank Campana; Moïse Namer
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
The oncologist 2010;15(8):799-809.
2009: ISABELLE RAY COQUARD; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras Hogendoorn; Philippe A Cassier; Armelle Dufresne; Jean-Yves Blay
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
Cancer research 2009;69(13):5383-91.
2009: Sana Intidhar Labidi; Thomas Bachelot; ISABELLE RAY COQUARD; Karim Mosbah; Isabelle Treilleux; Jerome Fayette; Bertrand Favier; Guillaume Galy; Jean-Yves Blay; Jean-Paul Guastalla
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
Clinical breast cancer 2009;9(2):118-21.
2008: Philippe A Cassier; ISABELLE RAY COQUARD; Marie-Pierre Sunyach; Laurence Lancry; Jean-Paul Guastalla; Céline Ferlay; Frédéric Gomez; Hervé Curé; Alain Lortholary; Line Claude; Jean-Yves Blay; Thomas Bachelot
A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer.
Cancer 2008;113(9):2532-8.
2008: Philippe A Cassier; Sylvie Chabaud; Véronique Trillet-Lenoir; Pierre-Yves Peaud; Jean-Dominique Tigaud; Hervé Cure; Hubert Orfeuvre; Bruno Salles; Claude Martin; Jean-Philippe Jacquin; Cecile Agostini; Jean-Paul Guastalla; David Pérol; Thomas Bachelot
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Breast cancer research and treatment 2008;109(2):343-50.
2008: Thomas Bachelot; Jean-Paul Guastalla; ISABELLE RAY COQUARD
[Adjuvant therapies: the example of breast cancer].
La Revue du praticien 2008;58(8):817-9.
2007: ISABELLE RAY COQUARD; Désiré Paraiso; Jean-Paul Guastalla; Bernard Leduc; F Guichard; C Martin; L Chauvenet; Z Haddad-Guichard; D Lepillé; Hubert Orfeuvre; H Gautier; D Castera; Eric Pujade-Lauraine
Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.
British journal of cancer 2007;97(9):1200-5.
2007: ISABELLE RAY COQUARD; Thomas Bachelot; Chadi Saba; Cyrille Confavreux; Jean-François Brantus; Fadi Rustam; Hervé Ghesquière; Catherine Sebban; Pierre Biron; Jean-Paul Guastalla; Jean-Yves Blay
[Are antiangiogenic antibodies universal for solid tumor?].
Bulletin du cancer 2007;94 Spec No():S191-6.
2007: Pierre Kerbrat; Henri Roché; Jacques Bonneterre; Corinne Veyret; Alain Lortholary; Alain Monnier; Pierre Fumoleau; Pierre Fargeot; Moïse Namer; Philippe Chollet; Marie-Josèphe Goudier; Bruno Audhuy; H Simon; Philippe Montcuquet; Jean-Christophe Eymard; S Walter; Pierre Clavère; Jean-Paul Guastalla
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
British journal of cancer 2007;96(11):1633-8.
2007: Godefridus J Peters; MD Clavel; Paul Noordhuis; G J Geyssen; Adrie C Laan; Jean-Paul Guastalla; H T Edzes; Jan B Vermorken
Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Journal of chemotherapy (Florence, Italy) 2007;19(2):212-21.
2007: François Golfier; C Labrousse; Lucien Frappart; Bruno Mathian; Jean-Paul Guastalla; Véronique Trillet-Lenoir; Touria Hajri; Anne-Marie Schott; Daniel Raudrant
[Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005].
Gynécologie, obstétrique & fertilité 2007;35(3):205-15.
2007: François Golfier; Daniel Raudrant; Lucien Frappart; Bruno Mathian; Jean-Paul Guastalla; Véronique Trillet-Lenoir; Fabien Vaudoyer; Touria Hajri; Anne-Marie Schott
First epidemiological data from the French Trophoblastic Disease Reference Center.
American journal of obstetrics and gynecology 2007;196(2):172.e1-5.
2007: marianne tuefferd; Jérôme Couturier; Françoise Penault-Llorca; Anne Vincent-Salomon; Philippe Broët; Jean-Paul Guastalla; Djelila Allouache; Martin Combe; Béatrice Weber; Eric Pujade-Lauraine; Sophie Camilleri-Broët
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.
PloS one 2007;2(11):e1138.
2006: Thierry Delozier; Jean-Paul Guastalla; Alejandro Yovine; Christelle Levy; Philippe Chollet; Mireille Mousseau; Rémi Delva; David Coeffic; Jean-Michel Vannetzel; Eliette-Sudriez Zazzi; Silvano Brienza; Esteban Cvitkovic
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Anti-cancer drugs 2006;17(9):1067-73.
2006: Hugues Bourgeois; Florence Joly; Eric Pujade-Lauraine; Hervé Cure; Jean-Paul Guastalla; Aurélie Ferru; Virginie Chabrun; Stéphanie Chieze; Jean-Marc Tourani
Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients.
American journal of clinical oncology 2006;29(4):399-404.
2006: Aman U Buzdar; Jean-Paul Guastalla; Jean-Marc Nabholtz; Jack Cuzick
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Cancer 2006;107(3):472-80.
2006: Henri Roché; Pierre Kerbrat; Jacques Bonneterre; Pierre Fargeot; Pierre Fumoleau; Alain Monnier; Pierre Clavère; Marie-Josèphe Goudier; Philippe Chollet; Jean-Paul Guastalla; Daniel Serin
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1221-7.
2006: ISABELLE RAY COQUARD; Chadi Saba; Thomas Bachelot; Pierre Méeus; Hervé Mignotte; Rémy Blondet; Isabelle Treilleux; Marie Peix; Jean-Paul Guastalla
[Neoadjuvant chemotherapy and ovarian cancer].
Bulletin du cancer 2006;93(7):669-76.
2006: Katy Foulmann; Jean-Paul Guastalla; Nadège Caminet; Véronique Trillet-Lenoir; Daniel Raudrant; François Golfier; Anne-Marie Schott
What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence.
Gynecologic oncology 2006;102(1):103-10.
2006: ISABELLE RAY COQUARD; Christophe Borg; Thomas Bachelot; Jérôme Fayette; Laura Zufferey; Jean-Paul Guastalla; Hervé Ghesquière; Jean-Yves Blay; Catherine Sebban; Perrine Marec-Bérard; Pierre Biron
[Prognostic factors for febrile neutropenia].
Bulletin du cancer 2006;93(5):501-6.
2006: Bruno Cutuli; Paul-Henri Cottu; Jean-Paul Guastalla; Hubert Mechin; Anne Costa; Rosemary Jourdan
A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients.
Breast cancer research and treatment 2006;95(1):55-64.
2005: Roland Bugat; Jean-Paul Guastalla; Jean-Louis Misset
[Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].
Bulletin du cancer 2005;92(11):1003-6.
2005: Christine Haie-Meder; Béatrice Fervers; Eric Fondrinier; Margaret Haugh; Catherine Lhomme; Jean-Paul Guastalla
SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1100-8.
2004: Véronique Diéras; Pierre Fumoleau; Gilles Romieu; Michèle Tubiana-Hulin; Moïse Namer; Louis Mauriac; Jean-Paul Guastalla; Eric Pujade-Lauraine; Pierre Kerbrat; Philippe Maillart; Frédérique Pénault-Llorca; Marc Buyse; Pierre Pouillart
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(24):4958-65.
2004: Pierre Fargeot; Jacques Bonneterre; Henri Roché; Alain Lortholary; Mario Campone; Isabelle Van Praagh; Alain Monnier; Moïse Namer; Simon Schraub; Jean-Claude Barats; Jean-Paul Guastalla; Marie-Josèphe Goudier; Isabelle Chapelle-Marcillac
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4622-30.
2004: Isabelle Treilleux; Jean-Yves Blay; Nathalie Bendriss-Vermare; ISABELLE RAY COQUARD; Thomas Bachelot; Jean-Paul Guastalla; Alain Bremond; Sophie Goddard; Jean-Jacques Pin; Clarisse Barthelemy-Dubois; Serge Lebecque
Dendritic cell infiltration and prognosis of early stage breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7466-74.
2004: Emilio Bajetta; Els Vercammen; Uwe Reinhardt; Riaz Janmohamed; Ricardo Marques da Costa; Ursula Matulonis; Jean-Paul Guastalla
Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
Tumori 2004;90(5):449-57.
2004: Catherine Lhommé; ISABELLE RAY COQUARD; Jean-Paul Guastalla; Anne Bataillard; Laurence Thomas; Pascal Bonnier; Daniel Dargent; Nicole Dohollou; Gérard Ganem; Jean-Pierre Lefranc; Jean-Louis Misset; Olivier Rixe; Xavier Tchiknavorian; Christophe Tournigand; Richard Villet; Thomas Bachelot; Pierre Kerbrat; Béatrice Fervers; Jean-Pierre Basuyau; Christine Cohen-Solal-le Nir; Philippe Morice; Pierre Duvillard; Eric Voog
[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)].
Bulletin du cancer 2004;91(7-8):609-20.
2004: Véronique Diéras; Jean-Paul Guastalla; Jean-Marc Ferrero; Hervé Curé; Béatrice Weber; Philippe Winckel; Alain Lortholary; Françoise Mayer; Désiré Paraiso; Emmanuelle Magherini; Eric Pujade-Lauraine
A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study.
Cancer chemotherapy and pharmacology 2004;53(6):489-95.
2004: Jean-Paul Guastalla; Thomas Bachelot; ISABELLE RAY COQUARD
[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials].
Bulletin du cancer 2004;91 Suppl 2():S99-108.
2004: Jean-Paul Guastalla; Thomas Bachelot; ISABELLE RAY COQUARD
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials].
Bulletin du cancer 2004;91 Spec No():S99-108.
2004: Jack Cuzick; Aman U Buzdar; Michael Baum; Raffaele Bianco; Robert Coleman; Manuel Constenla; Wolfgang Distler; Mitch Dowsett; John Forbes; Jean-Paul Guastalla; Joan Houghton; Norman Williams; Anthony Howell; Gershon Locker; John MacKey; Richard Sainsbury; Jeffrey Tobias
Adjuvant use of anastrozole in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1524-6; author reply 1526-7.
2003: Jean-Paul Guastalla; Véronique Diéras
The taxanes: toxicity and quality of life considerations in advanced ovarian cancer.
British journal of cancer 2003;89 Suppl 3():S16-22.
2003: ISABELLE RAY COQUARD; Thomas Bachelot; Catherine Sebban; Pierre Biron; Jean-Paul Guastalla; Jean-Yves Blay
[Anemia and chemotherapy].
Bulletin du cancer 2003;90 Spec No():S133-43.
2003: Michel Resbeut; Eric Fondrinier; Béatrice Fervers; Christine Haie-Meder; Anne Bataillard; Catherine Lhommé; Bernard Asselain; Jean-Pierre Basuyau; Alain Brémond; Damienne Castaigne; Jean-Bernard Dubois; Gilles Houvenaeghel; Eric Lartigau; Eric Leblanc; Xavier Sastre-Garau; Alice Sarradet; Jean-Paul Guastalla; Jean Chauvergne
[Standards, Options and Recommendations for the management of invasive cervical cancer patients (non metastastic)].
Bulletin du cancer 2003;90(4):333-46.
2003: ISABELLE RAY COQUARD; Thomas Bachelot; Jean-Paul Guastalla; Eric Levy; Jean-Dominique Tigaud; Pascal Vincent; Dominique Dramais; David Assouline; Eric Pujade-Lauraine
Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens.
Gynecologic oncology 2003;88(3):351-7.
2002: Jacques Bonneterre; Henri Roché; Alain Monnier; Jean-Paul Guastalla; Moïse Namer; Pierre Fargeot; Sylvie Assadourian
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
British journal of cancer 2002;87(11):1210-5.
2002: Thomas Bachelot; Frédéric Gomez; Pierre Biron; ISABELLE RAY COQUARD; P Soler-Michel; Irène Philip; Jean-Paul Guastalla; Paul Rebattu; Arlette Dumortier; Jean Pierre Droz; Jean-Yves Blay
A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients.
British journal of cancer 2002;87(10):1079-85.
2002: Alain Brémond; Anne Bataillard; Laurence Thomas; Jean-Louis Achard; Béatrice Fervers; Eric Fondrinier; Jacques Lansac; Corinne Bailly; Sylvette Hoffstetter; Jean-Pierre Basuyau; Joëlle d'Anjou; Philippe Descamps; Fadila Farsi; Jean-Paul Guastalla; François Laffargue; Jean-François Rodier; Pascal Vincent; Jacques Pigneux
[Standards, Options and Recommendations 2000 for the management of patients with endometrial cancer (non-metastatic)(abridged report)].
Gynécologie, obstétrique & fertilité 2002;30(11):902-16.
2002: Michel Resbeut; Eric Fondrinier; Béatrice Fervers; Christine Haie-Meder; Anne Bataillard; Catherine Lhommé; Bernard Asselain; Jean-Pierre Basuyau; Alain Brémond; Damienne Castaigne; Jean-Bernard Dubois; Gilles Houvenaeghel; Eric Lartigau; Eric Leblanc; Xavier Sastre-Garau; Frédéric Ternier; A Sarradet; Jean-Paul Guastalla; Jean Chauvergne
[Standards, options and recommendations for the management of patients with invasive cancer of the cervix uterus (non-metastatic stage), abridged version].
Gynécologie, obstétrique & fertilité 2002;30(7-8):631-48.
2001: Pierre Kerbrat; Catherine Lhommé; Béatrice Fervers; Jean-Paul Guastalla; L Thomas; Jean-Pierre Basuyau; Pierre Duvillard; C Cohen-Solal; J Dauplat; N Tournemaine; Thomas Bachelot; I Ray; Eric Voog
[Standards, options and recommendations for the management and initial care of patients with malignant epithelial ovarian tumors (abridged version)].
Gynécologie, obstétrique & fertilité 2001;29(11):853-66.
2001: Pierre Kerbrat; Catherine Lhommé; Béatrice Fervers; Jean-Paul Guastalla; L Thomas; Jean-Pierre Basuyau; Pierre Duvillard; C Cohen-Solal; J Dauplat; N Tournemaine; Thomas Bachelot; I Ray; Eric Voog
[Standards, options and recommendations for the initial management of patients with malignant ovarian epithelial tumors (abridged version) ].
Gynécologie, obstétrique & fertilité 2001;29(10):733-42.
2001: Bertrand Coiffier; Jean-Paul Guastalla; Eric Pujade-Lauraine; P Bastit
Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1617-23.
2001: Patrice Viens; Henri Roché; Pierre Kerbrat; P Fumoleau; Jean-Paul Guastalla; Thierry Delozier
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
American journal of clinical oncology 2001;24(4):328-35.
2001: Alain Brémond; Anne Bataillard; Laurence Thomas; Jean-Louis Achard; Béatrice Fervers; Eric Fondrinier; Jacques Lansac; Corinne Bailly; Sylvette Hoffstetter; Jean-Pierre Basuyau; Joëlle d'Anjou; Philippe Descamps; Fadila Farsi; Jean-Paul Guastalla; François Laffargue; Jean-François Rodier; Pascal Vincent; Jacques Pigneux
Cancer of the endometrium.
British journal of cancer 2001;84 Suppl 2():31-6.
2001: Michel Resbeut; Eric Fondrinier; Béatrice Fervers; Christine Haie-Meder; Anne Bataillard; Catherine Lhommé; Bernard Asselain; Jean-Pierre Basuyau; Alain Brémond; Damienne Castaigne; Jean-Bernard Dubois; Gilles Houvenaeghel; Eric Lartigau; Eric Leblanc; X Sastre-Garaud; Frédéric Ternier; Jean-Paul Guastalla; Jean Chauvergne
Carcinoma of the cervix.
British journal of cancer 2001;84 Suppl 2():24-30.
2001: Pierre Kerbrat; Catherine Lhommé; Béatrice Fervers; Jean-Paul Guastalla; L Thomas; N Tournemaine; Jean-Pierre Basuyau; C Cohen-Solal; Pierre Duvillard; Thomas Bachelot; I Ray; Eric Voog; J Dauplat
Ovarian cancer.
British journal of cancer 2001;84 Suppl 2():18-23.
2001: L Thomas; Anne Bataillard; Alain Brémond; Eric Fondrinier; Béatrice Fervers; J L Achard; J Lansac; C Bailly; Sylvette Hoffstetter; Jean-Pierre Basuyau; Joëlle d'Anjou; Philippe Descamps; Fadila Farsi; Jean-Paul Guastalla; François Laffargue; Jean-François Rodier; P Vincent; Jacques Pigneux
[Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2001;5(2):163-92.
2001: Alain Brémond; Anne Bataillard; Laurence Thomas; Jean-Louis Achard; Béatrice Fervers; Eric Fondrinier; Jacques Lansac; Corinne Bailly; Sylvette Hoffstetter; Jean-Pierre Basuyau; Joëlle d'Anjou; Philippe Descamps; Fadila Farsi; Jean-Paul Guastalla; François Laffargue; Jean-François Rodier; Pascal Vincent; Jacques Pigneux
[Standards, Options and Recommendations for the surgical management of carcinoma of the endometrium].
Bulletin du cancer 2001;88(2):181-98.
2001: P Fumoleau; Franck Chauvin; Moïse Namer; R Bugat; Michèle Tubiana-Hulin; Jean-Paul Guastalla; Thierry Delozier; Pierre Kerbrat; Yves Devaux; Jacques Bonneterre; A Filleul; MD Clavel
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):612-20.
2001: Eric Pujade-Lauraine; Hervé Curé; C Battista; Jean-Paul Guastalla; B Chiurazzi; M Fabbro; Nicole Tubiana-Mathieu; Hugues Bourgeois; Bruno Lioure; Désiré Paraiso; Jean-Pierre Lotz
High dose chemotherapy in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11 Suppl 1():64-7.
2000: Eric Pujade-Lauraine; Jean-Paul Guastalla; P Vincent
[Carboplatin in cancer of the ovary].
Bulletin du cancer 2000;87 Spec No():40-7.
2000: Thomas Bachelot; ISABELLE RAY COQUARD; Gilles Catimel; Claude Ardiet; Jean-Paul Guastalla; Arlette Dumortier; Franck Chauvin; Jean Pierre Droz; Thierry Philip; MD Clavel
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):151-6.
2000: Jérôme Alexandre; P Bleuzen; Jacques Bonneterre; W Sutherland; Jean-Louis Misset; Jean-Paul Guastalla; Patrice Viens; Sandrine Faivre; A Chahine; M Spielman; A Bensmaïne; Michel Marty; Mondher Mahjoubi; Esteban Cvitkovic
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):562-73.
2000: Patrice Nony; Jean-Paul Guastalla; Paul Rebattu; P Landais; M Lievre; L Bontemps; Roland Itti; J Beaune; X Andre-Fouet; Marc Janier
In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy.
Cancer chemotherapy and pharmacology 2000;45(5):375-80.
2000: Christine Haie-Meder; Béatrice Fervers; Jean Chauvergne; Eric Fondrinier; Catherine Lhommé; Anne Bataillard; Jean-Paul Guastalla; Michel Resbeut
[Concomitant radiochemotherapy for cancer of the cervix: critical analysis based on the Standards, Options and Recommendations methodology].
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2000;4(1):60-75.
1999: Catherine Lhommé; P Vennin; N Callet; Thierry Lesimple; J L Achard; Jean Chauvergne; Elisabeth Luporsi; P Chinet-Charrot; Bruno Coudert; J E Couette; Jean-Paul Guastalla; D Lebrun; S Ispas; Joëlle Blumberg
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.
Gynecologic oncology 1999;75(2):187-93.
1999: Jacques Bonneterre; M Spielman; Jean-Paul Guastalla; Michel Marty; P Viens; Philippe Chollet; Henri Roché; P Fumoleau; Louis Mauriac; Hugues Bourgeois; Moïse Namer; J P Bergerat; Jean-Louis Misset; L Trandafir; Mondher Mahjoubi
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
European journal of cancer (Oxford, England : 1990) 1999;35(10):1431-9.
1999: Christine Haie-Meder; Béatrice Fervers; Jean Chauvergne; Eric Fondrinier; Catherine Lhommé; Jean-Paul Guastalla; Michel Resbeut
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Bulletin du cancer 1999;86(10):829-41.
1999: Marc-André Mahé; P Fumoleau; Michel Fabbro; Jean-Paul Guastalla; P Faurous; P Chauvot; L Chetanoud; Jean-Marc Classe; Philippe Rouanet; Jean-François Chatal
A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3249s-3253s.
1998: Jean-Paul Guastalla; Eric Pujade-Lauraine; B Weber; H Cuŕe; Hubert Orfeuvre; Mireille Mousseau; P Vincent; Véronique Diéras; Nicole Tubiana-Mathieu; JP Jacquin; L Mignot; Bernard Leduc; Patrice Viens; D Pariso
Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):37-43.
1998: Brigitte Tranchand; Gilles Catimel; C Lucas; M Sarkany; G Bastian; E Evene; Jean-Paul Guastalla; Sylvie Négrier; Paul Rebattu; Arlette Dumortier; M Foy; F Grossin; B Mazier; M Froudarakis; N Barbet; MD Clavel; Claude Ardiet
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 1998;41(4):281-91.
1998: ISABELLE RAY COQUARD; Pierre Biron; Thomas Bachelot; Jean-Paul Guastalla; Gilles Catimel; Yacine Merrouche; Jean Pierre Droz; Franck Chauvin; Jean-Yves Blay
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Cancer 1998;82(1):134-40.
1998: M E Froudarakis; Gilles Catimel; Jean-Paul Guastalla; Paul Rebattu; MD Clavel
Phase II trial of navelbine and fluorouracil as second-line chemotherapy in metastatic breast carcinoma.
Oncology 1998;55(1):87-8.
1997: Eric Pujade-Lauraine; Jean-Paul Guastalla; B Weber; Hervé Curé; Hubert Orfeuvre; Mireille Mousseau; P Vincent; Véronique Diéras; Nicole Tubiana-Mathieu; JP Jacquin; L Mignot; Bernard Leduc; D Paraïso; Patrice Viens
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Seminars in oncology 1997;24(5 Suppl 15):S15-30-S15-35.
1997: Michel Rivoire; Isabelle Treilleux; Pierre Kaemmerlen; N Barbet; Jean-Paul Guastalla; J P Droz
Salvage liver surgery of a chemorefractory ovarian choriocarcinoma.
Gynecologic oncology 1997;65(1):185-7.
1997: Gilles Catimel; Marc Spielmann; Véronique Dieras; Michèle Tubiana-Hulin; Jacques Bonneterre; Pierre Pouillart; Louis Kayitalire; Jean-Paul Guastalla; N Graffand; F Garet; Arlette Dumortier; B Pellae-Cosset
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Seminars in oncology 1997;24(1 Suppl 3):S8-12.
1997: Jan B Vermorken; Jean-Paul Guastalla; S R Hatty; D E Seitz; B Tanis; C McDaniels; MD Clavel
Phase I study of gemcitabine using a once every 2 weeks schedule.
British journal of cancer 1997;76(11):1489-93.
1996: Catherine Lhommé; P Kerbrat; C Lejeune; Jean-Paul Guastalla; Pierre Fumoleau; A Goupil; J F Héron; M A Cassin; I Pruvot; J A Soares; M Chazard
Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.
Seminars in oncology 1996;23(5 Suppl 12):48-54.
1996: Eric Pujade-Lauraine; Jean-Paul Guastalla; N Colombo; P Devillier; Eric François; Pierre Fumoleau; A Monnier; M Nooy; L Mignot; R Bugat; C Marques; M Mousseau; G Netter; F Maloisel; S Larbaoui; M Brandely
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):343-50.
1996: Gilles Catimel; Marc Spielmann; Véronique Dieras; L Kayitalire; P Pouillart; Jean-Paul Guastalla; P Soler-Michel; N Graffand; F Garet; Arlette Dumortier; B Pellae-Cosset; M Chazard
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Seminars in oncology 1996;23(1 Suppl 1):24-7.
1995: Gilles Catimel; Guy G. Chabot; Jean-Paul Guastalla; Arlette Dumortier; C Cote; C Engel; Alain Gouyette; A Mathieu-Boué; Mondher Mahjoubi; M Clavel
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(2):133-40.
1995: Gilles Catimel; REGIS COQUARD; Jean-Paul Guastalla; Yacine Merrouche; N Le Bail; M K Alakl; Arlette Dumortier; M Foy; M Clavel
Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors.
Cancer chemotherapy and pharmacology 1995;35(3):246-8.
1994: Yacine Merrouche; Gilles Catimel; Paul Rebattu; Arlette Dumortier; Jean-Paul Guastalla; P O'Grady; M Clavel
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):549-51.
1994: Jean-Paul Guastalla; Catherine Lhomme; P Kerbrat; F Mayer; M Namer; P Goupil; P Charrot; J F Heron; M Chazard; I Richard
Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(2):127-32.
1994: Gilles Catimel; franck chauvin; Jean-Paul Guastalla; Paul Rebattu; P Biron; M Clável
FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(1):95-7.
1994: Jean-Paul Guastalla; Catherine Lhommé; J Dauplat; M Namer; J Bonneterre; F Oberling; P Pouillart; Pierre Fumoleau; P Kerbrat; N Tubiana
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S33-8.
1994: Stéphane Culine; Jean-Paul Guastalla; Christine Théodore; J P Droz
[Chemotherapy of urothelial tumors of the bladder].
Bulletin du cancer. Radiothérapie : journal de la Société française du cancer : organe de la société française de radiothérapie oncologique 1994;81(4):303-11.
1992: Jean-Paul Guastalla; Eric Pujade-Lauraine; N Colombo; N Namer; Pierre Fumoleau; A Monnier; M A Nooy; G Falkson; L Mignot; R Bugat
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group].
Pathologie-biologie 1992;39(9):831-2.
1992: D Y Ploin; Brigitte Tranchand; Jean-Paul Guastalla; Paul Rebattu; F Chauvin; M Clavel; Claude Ardiet
Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1311-5.
1991: P Kerbrat; J F Héron; Jean-Paul Guastalla; Catherine Lhomme; A Goupil; C Toussaint; A Rey; M Chazard; L Lenaz; M George
[Study of high doses of carboplatin as a first choice in the therapy of advanced ovarian cancers].
Bulletin du cancer 1991;78(12):1133-7.
1989: M J George; J F Heron; P Kerbrat; Jean Chauvergne; A Goupil; D Lebrun; Jean-Paul Guastalla; Moïse Namer; Roland Bugat; Y Ayme
Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.
Seminars in oncology 1989;16(2 Suppl 4):30-2.
1989: M Clavel; P Biron; F Chauvin; Jean-Paul Guastalla; Paul Rebattu; M el Foudeh
[Chemotherapy of cancer of the breast in the metastatic phase].
Bulletin du cancer 1989;76(1):75-85.
1989: Brigitte Tranchand; F Nasri; M Minuit; M Clavel; Jean-Paul Guastalla; S Gamand; Claude Ardiet
[Phase I pharmacokinetics of flavone-acetic acid].
Bulletin du cancer 1989;76(8):871-4.
1981: J J Viala; D Ville; B Coiffier; Paul Rebattu; Jean-Paul Guastalla
[Pure red cell aplasia and chronic leukemia. Usefulness of ferrokinetic measurements (author's transl)].
Nouvelle revue française d'hématologie 1981;23(4):213-8.
1981: J J Viala; F Berger; Jean-Paul Guastalla; J Vignal; J L Chassard; M Blanc
[Peliosis hepatis localized after epigastric irradiation (author's transl)].
Archives d'anatomie et de cytologie pathologiques 1981;29(2):118-20.
1981: C Martin; H Martin; J J Viala; Jean-Paul Guastalla
[Facial paralysis and generalized infectious diseases].
Journal français d'oto-rhino-laryngologie; audiophonologie, chirurgie maxillo-faciale 1981;30(1):11-7.